All In Biotech

NDA 021344 · Astrazeneca

Faslodex

Fulvestrant · Intramuscular · Estrogen Receptor Antagonist

Novel

Last checked: Nov 19, 2026Latest source record: Jan 19, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Apr 25, 2002

Approved uses

13

Original approval plus efficacy supplements

Registered trials

557

100 Phase 3, 120 recruiting

FAERS reports

33,513

27,136 serious, 5,028 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 25, 2020.

Monotherapy FASLODEX is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy FASLODEX is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. FASLODEX is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)

Mechanism: Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells. In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines. In in vivo tumor studies, fulvestrant delayed the establishment of tumors from xenografts...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • FASLODEX · FULVESTRANT 250MG/5ML (50MG/ML) · SOLUTION, INTRAMUSCULAR · Prescription · TE AO
  • FASLODEX · FULVESTRANT 125MG/2.5ML (50MG/ML) · SOLUTION, INTRAMUSCULAR · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fulvestrant" as an intervention, any sponsor and status, largest first.

All 557 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression4,341
  • fatigue4,249
  • nausea3,085
  • death2,782
  • diarrhoea2,684
  • neutropenia2,542
  • white blood cell count decreased2,247
  • metastases to bone2,179
  • neoplasm progression2,130
  • asthenia1,812
  • pain1,786
  • metastases to liver1,779

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200463
2005115
2006128
2007149
2008166
2009158
2010141
2011268
2012541
2013343
2014346
2015713
20161,522
20172,213
20182,278
20192,870
20203,607
20213,353
20223,238
20233,862
20242,760
20252,874
20261,805

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Faslodex (Fulvestrant)

2024 spending

$326K

Beneficiaries

28

176 claims

Per beneficiary

$11,654

$182.81 per unit

View as table
YearSpending
2020$1,642,589
2021$670,070
2022$444,289
2023$293,278
2024$326,309

Part B: Faslodex* (Fulvestrant*) · HCPCS J9395

2024 spending

$21.9M

Beneficiaries

17,770

135,166 claims

Per beneficiary

$1,232

2024 ASP limit $8.21 per unit

View as table
YearSpending
2020$169,176,633
2021$99,529,826
2022$38,648,983
2023$27,127,870
2024$21,891,999

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 388 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.